Background: The occurrence of hypoglycemia and hyperglycemia during the first days after transition to continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes has not been systematically studied in children. The aim of this prospective study was to demonstrate that the protocol applied in our diabetes clinic is safe at CSII initiation in children.
Methods: We assessed 22 pediatric patients with type 1 diabetes, using continuous glucose monitoring (CGM) before and after CSII initiation (±3 days).
Results: After CSII initiation, there was no difference in the rates of hypoglycemic events expressed as relative rates (RRs) per person-reading (RR = 0.85, = 0.52, 95% CI 0.52-1.39), as well as in the number of prolonged hypoglycemic events (>1 h) per day (RR = 1.12, = 0.56, 95% CI 0.75-1.68). We observed only a trend toward prolonged episodes of hyperglycemia after pump initiation (RR = 1.52, = 0.06, 95% CI 0.97-2.35).
Conclusion: Our study is the first to assess, through CGM and in a prospective way, the impact of a CSII initiation protocol on glycemic values. Our protocol provides a safe model to avoid hypoglycemia at CSII initiation in children.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01840358.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401867 | PMC |
| http://dx.doi.org/10.3389/fendo.2017.00084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression Analysis of Cyst Specific Protein (CSP21) and Cellulose Synthase II (CSII) Genes in Acanthamoeba castellanii Trophozoites Exposed to Silver Nanoparticles Conjugated with Elaeagnus umbellata.
Acta Parasitol
January 2025
Department of Molecular Biology and Genetics, Ordu University, Ordu, Turkey.
Article Synopsis
- Acanthamoeba species are protozoa that can cause serious eye and CNS infections, and current treatments are often ineffective, especially in specific areas like the eye.
- The study evaluates the effectiveness of ethanolic fruit extract of E. umbellata, silver nanoparticles derived from it, and lauric acid in killing Acanthamoeba trophozoites and protecting DNA from damage.
- Results show that these treatments can significantly kill trophozoites and prevent DNA damage, suggesting potential new options for treating Acanthamoeba infections.
Cutaneous Adverse Effects From Diabetes Devices in Pediatric Patients With Type 1 Diabetes Mellitus: Systematic Review.
JMIR Dermatol
November 2024
Rowan-Virtua School of Osteopathic Medicine, 113 Laurel Rd, Stratford, NJ, 08084, United States, 1 (856) 566-6789.
Article Synopsis
- Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSII) are essential treatments for type 1 diabetes (T1D), but they may cause dermatologic complications like contact dermatitis and lipodystrophies, which negatively affect glycemic control and patient adherence.
- A systematic review analyzed 30 studies focusing on dermatologic issues related to CGM and CSII in pediatric patients, finding that contact dermatitis was the most common complication reported.
- The findings highlight the need for better manufacturer transparency and further research to address how these skin complications may impact long-term T1D management in young patients.
A Qualitative Evidence Synthesis of Continuous Subcutaneous Insulin Infusion: Acceptability, Implementation, Equity.
Nurs Health Sci
December 2024
Network for Research on Chronicity, Primary Care, and Health Promotion, Red de Investigacion en Cronicidad Atencion Primaria y Prevencion y Promocion de la Salud, Barcelona, Spain.
This work provides a synthesis of the perceptions of people with type 1 diabetes mellitus (T1DM) and healthcare professionals about the acceptability, implementation, and equity of continuous subcutaneous insulin infusion (CSII). A qualitative evidence synthesis was carried out. Three online databases (Medline, Embase, and Web of Science) were searched.
View Article and Find Full Text PDFCost-effectiveness of the tandem t: Slim X2 with control-IQ technology automated insulin delivery system in children and adolescents with type 1 diabetes in Sweden.
Diabet Med
November 2024
MedEngine DK ApS, Copenhagen, Denmark.
Aims: The present analysis estimated the cost-effectiveness of treatment with the Tandem t: slim X2 insulin pump with Control IQ technology (CIQ) in children with type 1 diabetes in Sweden.
Methods: A four-state Markov model and probabilistic sensitivity analyses (PSA) were used to assess the cost-effectiveness of CIQ use compared with treatment with multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII) in conjunction with CGM. Data sources included clinical input data from a recent retrospective, observational study, cost data from local diabetes supply companies and government agencies, and published literature.
Assessment of insulin dose changes in pediatric patients with type 1 diabetes mellitus starting on continuous subcutaneous insulin infusion.
J Clin Transl Endocrinol
September 2024
Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Objective: To assess change in total daily dose (TDD) of insulin following a switch from subcutaneous (SC) injections to continuous subcutaneous insulin infusion (CSII) in pediatric patients with type 1 diabetes (T1D). Secondary objectives were to determine the change in %basal insulin, insulin to carbohydrate (I:C) ratios, insulin sensitivity factor (ISF), and HbA1c/IDAA1c.
Methods: A retrospective chart review of patients < 18 years of age who transitioned from SC to CSII at the Alberta Children's Hospital (Calgary, Alberta, Canada) between January 2019 and March 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!